Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-06-14

Clinical Trial Update: An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating golimumab for ulcerative colitis was terminated, and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SIMPONI ARIA (GOLIMUMAB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2013-06-14